Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic
disease with significant impact on health-related quality of life (HRQoL). Patient-reported …

Objective Comparison of oral corticosteroid (OCS) use in patients with SLE in a US
rheumatology network pre-and post-belimumab initiation. Methods This retrospective cohort …

Aim: To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus
standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus …

Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …

Introduction: Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting
many different organ systems. Although disease manifestations are varied across the lupus …

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients
with systemic lupus erythematosus (SLE). Methods Patients with moderate‐to‐severe SLE …

Background Certain baseline factors in the BLISS trials were associated with high disease
activity and identified as predictors of improved belimumab response. Objectives We …

This study evaluated the real-world effectiveness of belimumab (BLM) in the treatment of
systemic lupus erythematosus (SLE) patients with moderate to high disease activity. This …

The March 2011 approval of belimumab (Benlysta) by the US Food and Drug Administration
has left rheumatologists in a bit of a quandary regarding its use. It is officially intended for …

Background Belimumab was the first biological drug approved for Systemic Lupus
Erythematosus (SLE). There is not a review focusing on all real-life experience with …